

## **Correction: Notice of Annual General Meeting of Redsense Medical AB (publ)**

The correction concerns the wording of item 13 and update of the weekdays mentioned in the Notice of the Annual General Meeting.

## **NOTICE OF ANNUAL GENERAL MEETING OF REDSENSE MEDICAL AB (PUBL.)**

Redsense Medical AB (publ), reg. no. 556646-4862 will hold an Annual General Meeting on Wednesday, May 8, 2024 at 4:30 PM, at Profilhotels Halmstad Plaza, Anna Lindhs Plats, 302 66 Halmstad, Sweden. Registration will take place from 4:00 PM. Light refreshments will be served before the Annual General Meeting, and the company's products will be on display.

### **RIGHT TO ATTEND AND NOTIFICATION OF PARTICIPATION TO THE COMPANY**

Shareholders who wish to participate at the Annual General Meeting shall:

Firstly: shall be entered in the share register, maintained by Euroclear Sweden AB, as of Monday, April 29, 2024,

Secondly: notify the company of their intention to participate no later than Thursday, May 2, 2024.

Notification of participation shall be made by e-mail to [info@redsensemecical.com](mailto:info@redsensemecical.com), or in writing to the company at the address: Redsense Medical AB, Box 7088, 300 07 Halmstad, Sweden. When submitting the notification, please state your name or company, personal identification number or organization number, address, and daytime telephone number. The notification procedure as above also applies to the notification of advisors.

### **NOMINEE-REGISTERED SHARES**

Shareholders whose shares who are registered in the name of a nominee must, in order to have the right to attend the Annual General Meeting, ensure that the nominee registers the shares in the shareholder's own name, so that the shareholder is registered in the share register, maintained by Euroclear Sweden AB, on Monday, April 29, 2024. Such registration may be temporary.

### **PROXY AND POWER OF ATTORNEY FORM**

Shareholders who are not present in person at the Annual General Meeting may exercise their right at the Annual General Meeting via a proxy with a written, signed, and dated power of attorney. A power of attorney form is available on the company's website, [www.redsensemecical.com](http://www.redsensemecical.com). The power of attorney form can also be obtained from the company at the above address. If the power of attorney was issued by a legal entity, a copy of the registration certificate or corresponding authorization document for the legal entity shall be attached. A power of attorney may not be older than one year, unless a longer period of validity is specified in the power of attorney, though no longer than five years. To facilitate entry at the Annual General Meeting, powers of attorney, registration certificates, and other authorization documents should be made available to the company well in advance of the Annual General Meeting.

## **PROPOSED AGENDA**

1. Opening of the Annual General Meeting
2. Election of the Chair of the Annual General Meeting
3. Preparation and approval of the voting register
4. Approval of the agenda
5. Election of one or two persons to attest the minutes
6. Determination of whether the Annual General Meeting has been duly convened
7. Presentation of the submitted Annual Report
8. Resolutions
  - a) on the adoption of the Annual Report;
  - b) on appropriations with regard the result according to the adopted balance sheet; and
  - c) on the discharge from liability for the Board members and the CEO
9. Determination of the number of Board members, deputy Board members, and number of auditors and deputy auditors
10. Determination of the fees to the Board of Directors and the auditor
11. Election of the Board of Directors and the auditor, as well as any deputy Board members and deputy auditors
12. Resolution on instructions to the Nomination Committee
13. Resolution on issue authorization
14. Close of the Annual General Meeting

## **RESOLUTION PROPOSALS**

### **Election of the Chair of the Annual General Meeting (item 2)**

The Nomination Committee proposes that Eva Walde be appointed Chair of the Annual General Meeting.

### **Resolution on appropriations with regard the result according to the adopted balance sheet (item 8.b)**

The Board of Directors proposes that the funds available for distribution be appropriated so that SEK 37 045 463 is carried forward.

**Resolution on the determination of the number of Board members, deputy Board members, and number of auditors and deputy auditors; resolution on the determination of the fees to the Board of Directors and the auditor; election of the Board of Directors and the auditor, as well as any deputy Board members and deputy auditors; and resolution on instructions to the Nomination Committee (items 9-11)**

The company's Nomination Committee proposes the following:

Item 9

That the Board of Directors, for the period up to the end of the next Annual General Meeting, shall consist of five Board members, elected by the Annual General Meeting, without deputies. That the company shall have one auditor, without a deputy.

Item 10

That the fees to the Board of Directors, for the period up to the end of the next Annual General Meeting, shall be issued at a rate of SEK 250 000 for the Chair of the Board and SEK 125 000 each for the Board members who do not receive a salary from the company. When evaluating the fees, a comparison has been made in relation to the fees in companies of similar size and complexity. On this basis, the Nomination Committee deems that the proposed increase is reasonable and well-motivated.

Furthermore, it is proposed that the fee to the auditor shall be paid in the amount according to the approved invoice.

Item 11

The Nomination Committee proposes the re-election of Eva Walde as Chair of the Board. As for Board members, the Nomination Committee proposes the re-election of Malin Almgren, Susanne Olausson, Lena Oswald, and Eva Walde, and new election of Martin Roos.

**Martin Roos** is an INSEAD-certified Board member (IDP), with experience in board work and management from telecom, technology, and biotechnology. He is currently Chair of the Board of Seamless Distribution Systems, and is a Board member of Nexam Chemicals (listed on Nasdaq First North). He is also a Board member in several startups, such as Lignin Industries (bioplastics from wood). Martin was previously a member of the operational Board Committee for the telecom operator WOM in Chile, was CEO of Cable and Wireless Caribbean and Altice in the Dominican Republic (integrated Orange with Tricom), and held senior positions in Ericsson. During his time at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin has a master's degree in economics from the Stockholm School of Economics, and a master's degree in chemical engineering from the Royal Institute of Technology in Stockholm.

Martin Roos is independent in relation to the company and its management, as well as major shareholders.

Information on the proposed Board members is available on the company's website, [www.redsensemedical.com](http://www.redsensemedical.com).

KPMG, with lead auditor Andreas Johansson, is proposed to be re-elected as the auditor.

### **Resolution on instructions to the Nomination Committee (item 12)**

The Nomination Committee proposes that the Annual General Meeting resolve that the following instructions shall apply as Nomination Committee instructions for the Nomination Committee until new instructions are decided.

The Nomination Committee shall consist of representatives of the three largest shareholders in terms of votes, in accordance with the share register, maintained by Euroclear Sweden, as of September 30 each year. The Chair of the Board shall convene the Nomination Committee for its first meeting, and also be co-opted to the Nomination Committee.

The member who represents the largest shareholder in terms of votes shall be appointed Chair of the Nomination Committee.

If one or more shareholders who appointed members of the Nomination Committee earlier than three months prior to the Annual General Meeting no longer belong to the three largest shareholders in terms of votes, members appointed by these shareholders shall make their place(s) available and the shareholder(s) who were added among the three shareholders with the largest number of votes shall have the right to appoint one member each. In the event that a member leaves the Nomination Committee before its work is completed, and the Nomination Committee deems it desirable that a replacement be appointed, such a replacement shall represent the same shareholder or, if this no longer belongs to one of the three largest shareholders in terms of votes, the shareholder who is next in line in terms of size. Changes in the composition of the Nomination Committee shall be announced immediately.

The composition of the Nomination Committee prior to each Annual General Meeting shall be announced no later than the third week in October, and the Nomination Committee's work shall commence as soon as possible after it is announced. No remuneration shall be paid to the members of the Nomination Committee. The company shall pay the necessary overheads that the Nomination Committee incurs in connection with its work. The Nomination Committee's term of office runs until the composition of the next Nomination Committee is announced.

The Nomination Committee draws up proposals on the following matters, to be resolved by the Annual General Meeting:

- a. A proposal on the Chair of the Annual General Meeting;
- b. A proposal on the number of Board members;
- c. A proposal on the Board members and Chair of the Board;
- d. A proposal on the Board fees for Board members appointed by the Annual General Meeting who are not appointed by the company, with a division between the Chair and other members, as well as, where applicable, remuneration for committee work, divided among each member;
- e. A proposal on the auditor(s) and auditor fees; and
- f. To the extent deemed necessary, a proposal on changes to these instructions for the Nomination Committee.

### **Resolution on issue authorization (item 13)**

The Board of Directors proposes that the Annual General Meeting authorizes the Board of Directors an issue authorization, as follows.

The Board of Directors is authorized to, on one or more occasions, up to the next Annual General Meeting, decide on the new issue of shares, the issue of subscription warrants, and/or the issue of convertibles. Issuance shall be possible with or without deviation from the shareholders' preferential rights. By decision supported by the authorization, a maximum number of shares may be issued in the event of a new issue of shares, through the exercise of subscription warrants and/or when converting convertibles, that corresponds to 20 percent of the total number of outstanding shares in the company at the time when the authorization is exercised for the first time (which does not prevent subscription warrants and convertibles from being accompanied by conversion terms which, if applied, may result in a different number of shares).

The authorization includes the right to decide on an issue with cash payment, payment with non-material property, or payment by offset, and can otherwise be combined with conditions referred to in chapter 2, section 5, second paragraph, items 1-3 and 5, of the Swedish Companies Act.

### **SPECIAL MAJORITY REQUIREMENTS**

For a valid resolution, according to item 13, the proposal shall be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the Annual General Meeting.

### **DOCUMENTATION**

Complete proposals, as well as accounting documentation and the audit report for 2023, will be available, no later than three weeks before the General Meeting, at the company and on the company's website [www.redsensemedical.com](http://www.redsensemedical.com), and will be sent immediately, and at no cost to the recipient, to shareholders who request it and provide their postal address. The documentation will also be made available at the General Meeting.

### **INFORMATION AT THE GENERAL MEETING**

Shareholders are reminded of their right to request information from the Board of Directors and the CEO at the General Meeting, in accordance with chapter 7, section 32 of the Swedish Companies Act.

### **PROCESSING OF AV PERSONAL DATA**

For information on how your personal data is processed, please see:

<https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf>.

---

Halmstad, April 2024

**Redsense Medical AB (publ.)**

*The Board of Directors*

**Contact information**

For further information, please contact:

Pontus Nobréus

CEO

Telephone: +46 72-171 1264

E-mail: [pontus.nobreus@redsensemedical.com](mailto:pontus.nobreus@redsensemedical.com)

Redsense Medical AB (publ.), 556646-4862

**ABOUT REDSENSE MEDICAL**

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.

**Disclaimer**

*This document is a translation of the Swedish language version. In the event of any discrepancies between this translation and the original Swedish document, the latter shall be deemed correct.*